顺铂不同途径给药在卵巢癌化疗中的作用  

THE EFFECT OF CISPLATIN THROUGH DIFFERENT ROUTES ON THE CHEMOTHERAPY OF OVARIAN CANCER

作　　者：陈建国[1] 郑伟[1] 李爱玲 

机构地区：[1]河南省人民医院妇科,郑州450003

出　　处：《癌症》1993年第3期235-237,共3页Chinese Journal of Cancer

摘　　要：对57例病理证实为卵巢癌的患者以顺铂为主经不同途径给药化疗。其中静脉给药(静化组)22例,共121个疗程;腹腔给药(腹化组)35例,共161个疗程。比较两组患者生存时间。发现静化组与腹化组Ⅰ、Ⅱ期卵巢癌患者平均生存时间分别为29.57±16.32月(±S)和31.40±20.54月。经统计学处理两者之间无显著差异(P>0.05)。而腹化组晚期(Ⅲ、Ⅳ期)患者的平均生存时间(18.10±10.23月)显著长于静化组晚期患者(11.63±6.33月、P<0.01)。实验结果表明顺铂经腹腔给药对于晚期卵巢癌患者是一种有希望的化疗方法。57 patients with ovarian cancer were treated by cisplatin containing chemotherapy through different routes. Among them 22 were received intravenous chemotherapy (IV group) they had totally 121 courses, and 35 were received intraperitoneal chemotherapy (IP group) had 161 courses. The mean survival times showed no significant differ ence (P>0.05) between the I, II stage patients of toe two groups, which were 29.57± 16.32 months (x±s) and 31.40±20.54 months, respectively. .However, for the advanced ovarian cancer patients (III, IV stage), the result showed that the mean survival time of IP group (18.10±10.23 months) was significantly longer than that of IV group(11.63± 6.33 months) (P<0.01). Our experiences suggested that the intraperitoneal chemotherapy of cisplatin is more suitable for advanced ovariad cancer patients.

关 键 词：顺铂 卵巢肿瘤 药物疗法 

分 类 号：R737.310.5[医药卫生—肿瘤]